Chiesi and Inhalation CDMO Bespak have announced an expansion of an existing partnership to increase manufacturing capacity for LGWP propellant MDIs at Bespak’s Holmes Chapel, UK site. Chiesi announced plans to launch an HFA 152a inhaler by the end of 2025 in December 2019. In October 2025, the company said that the FDA had accepted an NDA for an HFA 152a formulation of its Trimbow beclomethasone dipropionate / formoterol fumarate / glycopyrrolate MDI.
In March 2025, Chiesi announced plans for an LGWP MDI manufacturing facility in Nerviano, Italy and later that year, the company inaugurated an expansion of its site in La Chaussée-Saint-Victor, France, to support manufacture of LGWP MDIs. Bespak spun out from Recipharm in 2024 specifically to focus on the LGWP propellant transition. In 2024, Bespak and Presspart announced the launch of GMP pilot-scale MDI filling line for LGWP propellants at the Holmes Chapel site.
Bespak CEO Chris Hirst commented, “Our collaboration with Chiesi has grown over time around a shared commitment to patient safety, technical excellence and sustainability. By deepening this partnership, we are accelerating the transition to low carbon pMDIs and reinforcing the UK’s role as a center of excellence for sustainable inhalation manufacturing. This is a position being recognized by the wider industry, leading to our Holmes Chapel site being selected as a key source of supply by leading brand owners like Chiesi, cementing our role as a strategic supply chain partner for the next generation propellant inhalers and innovative nasally-delivered therapies.”
Chiesi Group Vice Chair Maria Paola Chiesi said, “At Chiesi, sustainability is not an add-on; it is a commitment that guides our strategic choices. We know that inhalers are essential treatments, and that the environmental impact associated with them must be addressed without shifting the burden onto patients. The partnership with Bespak reinforces our efforts to reduce emissions across the value chain, while protecting access, quality and trust. Climate action and patient care must continue to advance hand in hand.”
Read the Chiesi and Bespak press release
